Onconova Therapeutics Inc (NASDAQ:ONTX)’s share price has entered into oversold territory with an RSI value of 19.3. The Zacks Consensus Estimate for Onconova Therapeutics Inc (NASDAQ:ONTX) for the full year period has improved 75 cents over the past two months to $-2.09 per share. Currently, Onconova Therapeutics Inc (NASDAQ:ONTX) has a Zacks Rank #2 (Buy), suggesting that now might be a good time to get in on Onconova Therapeutics Inc (NASDAQ:ONTX) after its recent drop. Onconova Therapeutics Inc (NASDAQ:ONTX) stock performance was -6.11% in last session and finished the day at $5.69. Traded volume was 528,196.00million shares in the last session and the average volume of the stock remained 363.45K shares. Onconova Therapeutics Inc (NASDAQ:ONTX) insider ownership is 27.60%.
Investors in Array BioPharma Inc. (NASDAQ:ARRY) saw new options begin trading this week, for the May 17th expiration. It was looked up and down the ARRY options chain for the new May 17th contracts. Array Biopharma Inc (NASDAQ:ARRY) dropped -5.01 percent to $4.17 Friday on volume of 2.45million shares. The intra-day range of the stock was $4.09 to $4.52. Array Biopharma Inc (NASDAQ:ARRY) has a market capitalization of $523.15million.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has an annual cash incentive program, which is designed to provide cash bonus awards to the Company’s employees, including the Company’s executive officers. On March 27, 2014, the independent members of the Board of Directors (the “Independent Board Members”) of the Company, upon the recommendation of the Company’s compensation committee (the “Compensation Committee”), established the corporate goals under the 2014 annual cash incentive award program for the year ending December 31, 2014. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)’s stock on Apr 04, 2014 reported a decrease of -4.67% to the closing price of $1.43. Its fifty two weeks range is $1.42-$8.40. The total market capitalization recorded $74.06million. The overall volume in the last trading session was 608,017.00million shares. In its share capital, AVEO has 51.79million outstanding shares.
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) today announced that it has appointed José Baselga M.D., Ph.D. and Jeff Berkowitz as independent members of its board of directors. Dr. Baselga, physician-in-chief at Memorial Sloan Kettering Cancer Center, is an accomplished clinician and a thought leader in the PI3K field. On Friday, shares of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) dropped -3.01% to close the day at $10.62. Company monthly performance is recorded as -25.68%. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) quarterly revenue growth is -18.06%.